Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,340
Distinct drugs
372
Records naming a cancer
982
Dated in the last 12 months
182
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 49 | Sep 22, 2026 |
| EMA | EU | 459 | 245 | 385 | 74 | 18 | Jul 20, 2026 |
Data updated 18 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as NTP-BICALUTAMIDE (DIN 02358557) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02358557 | withdrawnsource: Cancelled Pre Marketsince Aug 6, 2015 | health-canada-dpd |
| — | Pazopanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VOTRIENT (DIN 02352311) under ATC L01EX03 PAZOPANIB. Indications are not published in the Drug Product Database — see… | DIN02352311 | withdrawnsource: Cancelled Pre Marketsince Jul 8, 2020 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as CO LETROZOLE (DIN 02352052) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02352052 | withdrawnsource: Cancelled Pre Marketsince Sep 1, 2017 | health-canada-dpd |
| — | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARABINE PHOSPHATE FOR INJECTION (DIN 02351730) under ATC L01BB05 FLUDARABINE. Indications are not published in… | DIN02351730 | withdrawnsource: Cancelled Pre Marketsince Aug 28, 2024 | health-canada-dpd |
| — | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as NU-BICALUTAMIDE (DIN 02336545) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02336545 | withdrawnsource: Cancelled (Unreturned Annual)since Mar 28, 2018 | health-canada-dpd |
| — | Vincristine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINCRISTINE SULFATE INJECTION USP (DIN 02333198) under ATC L01CA02 VINCRISTINE. Indications are not published in the… | DIN02333198 | withdrawnsource: Cancelled Pre Marketsince Mar 12, 2021 | health-canada-dpd |
| — | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02333023) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02333023 | approved | health-canada-dpd |
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUTENT (DIN 02328607) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see… | DIN02328607 | withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025 | health-canada-dpd |
| — | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINORELBINE TARTRATE INJECTION USP (DIN 02327643) under ATC L01CA04 VINORELBINE. Indications are not published in the… | DIN02327643 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2018 | health-canada-dpd |
| — | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as IPG-ANASTROZOLE (DIN 02326094) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02326094 | approved | health-canada-dpd |
| — | Vincristine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINCRISTINE SULFATE INJECTION (DIN 02324148) under ATC L01CA02 VINCRISTINE. Indications are not published in the Drug… | DIN02324148 | withdrawnsource: Cancelled Pre Marketsince Aug 7, 2017 | health-canada-dpd |
| — | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02323001) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02323001 | withdrawnsource: Cancelled Pre Marketsince Aug 17, 2017 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-LETROZOLE (DIN 02322544) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02322544 | withdrawnsource: Cancelled Pre Marketsince Nov 2, 2016 | health-canada-dpd |
| — | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02322242) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02322242 | approved | health-canada-dpd |
| — | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBIF (DIN 02318288) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database… | DIN02318288 | withdrawnsource: Cancelled Pre Marketsince Jul 8, 2024 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-LETROZOLE (DIN 02316374) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02316374 | withdrawnsource: Cancelled Pre Marketsince May 30, 2025 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHL-LETROZOLE (DIN 02316366) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02316366 | withdrawnsource: Cancelled Pre Marketsince Sep 13, 2017 | health-canada-dpd |
| — | Panitumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as VECTIBIX (DIN 02308495) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database —… | DIN02308495 | approved | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL FOR INJECTION (DIN 02285363) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02285363 | approved | health-canada-dpd |
| — | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE (DIN 02283697) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02283697 | approved | health-canada-dpd |
| — | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as AVONEX (DIN 02267594) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product… | DIN02267594 | approved | health-canada-dpd |
| — | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFOSFAMIDE FOR INJECTION (DIN 02246566) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug… | DIN02246566 | withdrawnsource: Cancelled Pre Marketsince Aug 16, 2023 | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-PACLITAXEL FOR INJECTION (DIN 02243392) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02243392 | withdrawnsource: Cancelled Pre Marketsince Oct 16, 2015 | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PAXENE (DIN 02241957) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product Database — see… | DIN02241957 | withdrawnsource: Cancelled (Unreturned Annual)since Mar 28, 2018 | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL INJECTION (DIN 02241443) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product… | DIN02241443 | withdrawnsource: Cancelled (Unreturned Annual)since Mar 28, 2018 | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL (DIN 02241314) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product Database —… | DIN02241314 | withdrawnsource: Cancelled Pre Marketsince Oct 16, 2015 | health-canada-dpd |
| — | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LEUPROLIDE ACETATE INJECTION (DIN 02240264) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug… | DIN02240264 | withdrawnsource: Cancelled Pre Marketsince Oct 16, 2015 | health-canada-dpd |
| — | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as NU-FLUTAMIDE TABLETS (DIN 02239082) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product… | DIN02239082 | withdrawnsource: Cancelled (Unreturned Annual)since Mar 28, 2018 | health-canada-dpd |
| — | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ETOPOSIDE (DIN 02237873) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database —… | DIN02237873 | withdrawnsource: Cancelled Pre Marketsince Sep 12, 2017 | health-canada-dpd |
| — | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-ETOPOSIDE (DIN 02237872) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database… | DIN02237872 | withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017 | health-canada-dpd |
| — | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ETOPOSIDE (DIN 02237871) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database… | DIN02237871 | withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017 | health-canada-dpd |
| — | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-TAMOXIFEN (DIN 02237599) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database… | DIN02237599 | withdrawnsource: Cancelled Pre Marketsince Oct 25, 2016 | health-canada-dpd |
| — | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-TAMOXIFEN (DIN 02237598) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database… | DIN02237598 | withdrawnsource: Cancelled Post Marketsince Oct 25, 2016 | health-canada-dpd |
| — | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPOSIN (DIN 02237428) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see… | DIN02237428 | withdrawnsource: Cancelled Pre Marketsince Aug 1, 2017 | health-canada-dpd |
| — | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PENTA-FLUTAMIDE (DIN 02233019) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product… | DIN02233019 | withdrawnsource: Cancelled (Unreturned Annual)since Apr 5, 2018 | health-canada-dpd |
| — | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as PENTA-TAMOXIFEN TABLETS (DIN 02232552) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN02232552 | withdrawnsource: Cancelled (Unreturned Annual)since Apr 5, 2018 | health-canada-dpd |
| — | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as PENTA-TAMOXIFEN TABLETS (DIN 02232551) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product… | DIN02232551 | withdrawnsource: Cancelled (Unreturned Annual)since Apr 5, 2018 | health-canada-dpd |
| — | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOM-FLUTAMIDE (DIN 02230524) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database… | DIN02230524 | withdrawnsource: Cancelled Pre Marketsince Mar 26, 2025 | health-canada-dpd |
| — | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUPRON DEPOT (DIN 02148730) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database… | DIN02148730 | withdrawnsource: Cancelled Pre Marketsince Jun 22, 2016 | health-canada-dpd |
| — | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUPRON DEPOT (DIN 02148722) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database… | DIN02148722 | withdrawnsource: Cancelled Pre Marketsince Jun 22, 2016 | health-canada-dpd |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.